Vilazodone for the Treatment of Depression: An Update

Wang, Sheng‐Min; Han, Changsu; Lee, Soo-Jung; Patkar, Ashwin A.; Masand, Prakash S.; Pae, Chi‐Un

doi:10.4068/cmj.2016.52.2.91

Cited by 41 publications

(21 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is suggested that the dose be slowly titrated from 1 mg twice daily, by doubling the dosage daily to avoid orthostatic hypotension [42,43]. Iloperidone demonstrates high binding affinity for D 2 and D 3 receptors, α1-adrenergic receptors, and 5-HT 2 A [42]; however, receptor affinity for D 2 and 5-HT 2 A, is low compared with other antipsychotics such as lurasidone and asenapine [44]. Iloperidone demonstrates moderate affinity for α2 receptors, and therefore may have greater risk of orthostatic hypotension [45,46].…”

Section: Iloperidonementioning

confidence: 99%

“…Iloperidone demonstrates moderate affinity for α2 receptors, and therefore may have greater risk of orthostatic hypotension [45,46]. It also shows mild antagonism on 5-HT 1A receptors [44]. Finally, it exhibits minimal affinity for H1 receptors, thus theoretically offering limited sedation and weight gain [46].…”

Section: Iloperidonementioning

confidence: 99%

“…It is therefore recommended that the dose be reduced by 50% when coadministered with potent inhibitors of these cytochrome systems. There are no adjustment recommendations in patients with hepatic or renal impairment, however, Sedek et al, noted a doubling of half-life in patients with renal impairment compared with healthy controls (33.7 vs. 15 h; p < 0.05) [44,47].…”

Section: Iloperidonementioning

confidence: 99%

See 2 more Smart Citations

A Review of the Pharmacological and Clinical Profile of Newer Atypical Antipsychotics as Treatments for Bipolar Disorder: Considerations for Use in Older Patients

et al. 2018

View full text Add to dashboard Cite

Bipolar disorder prevalence rates vary in the older adult population (defined as age ≥ 65 years), ranging from 1% in community dwellers to as high as 8-10% in hospital inpatients. Although older agents, including lithium and valproic acid, offer significant antimanic efficacy, as supported by a recent randomized controlled trial (RCT), there is growing interest in using atypical antipsychotics to treat bipolar disorder in older adults. Newer atypical antipsychotics are of interest based on their tolerability and efficacy in the general adult bipolar population. The aim of this review was to systematically examine efficacy and tolerability of newer atypical antipsychotics for older adult bipolar disorder (OABD). We conducted a systematic search utilizing the MEDLINE, EMBASE, PsycINFO and Cochrane Library electronic databases, with the aim of identifying all RCTs comparing newer atypical antipsychotics approved by the US FDA since 2002 (including brexpiprazole, cariprazine, lurasidone, iloperidone, asenapine, paliperidone, and aripiprazole) with placebo or another comparator, in the treatment of any phase of bipolar disorder (including mania, depression or mixed episodes while used as an acute or maintenance treatment) in older adults (> 65 years). We found no RCT data on any of the examined agents. Hence, we changed our search criteria to include studies with a lower age cut-off (≥ 55 years), as well as the inclusion of post hoc studies. Two post hoc studies on lurasidone suggest its reasonable safety and efficacy profile in the acute and maintenance treatment of OABD; however, there are no pharmacoeconomic data on the use of lurasidone in the treatment of OABD. Research data from open-label studies on oral asenapine and aripiprazole as add-on therapy suggest that these two agents are adequately tolerated and improved symptoms of depression and mania in OABD; hence, there is an urgent need to conduct RCTs on these two agents. Lastly, we found no studies for the treatment of OABD with brexpiprazole, cariprazine, iloperidone, or paliperidone.

show abstract

Section: Iloperidonementioning

confidence: 99%

Section: Iloperidonementioning

confidence: 99%

Section: Iloperidonementioning

confidence: 99%

See 1 more Smart Citation

A Review of the Pharmacological and Clinical Profile of Newer Atypical Antipsychotics as Treatments for Bipolar Disorder: Considerations for Use in Older Patients

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Клинические данные, полученные на взрослых пациентах, свидетельствуют о том, что лечение депрессий комбинацией ингибитора обратного захвата серотонина (5-HT) флуоксетина и агонистов серотонинергических рецепторов типа 1А (5-HT1A-рецептор) имеет более высокий терапевтический эффект по сравнению с эффектом одного флуоксетина [13]. Действительно, флуоксетин не у каждого пациента, страдающего депрессией, вызывает улучшение состояния, более того, флуоксетин в период беременности нарушает нормальное развитие плода.…”

Section: вст уплениеunclassified

Correction of pain-related and affective behavior by combination of fluoxetine and buspirone in prenatally stressed rats

et al. 2018

View full text Add to dashboard Cite

The inhibitor of serotonin (5-HT) reuptake fluoxetine does not cause any improvement in every patient suffering from depression; moreover, fluoxetine during pregnancy disrupts the normal development of the fetus. Clinical observations in adult patients suggest that treatment of depression with a combination of fluoxetine and 5-HT1A receptor agonists has a higher therapeutic effect than the effect of a single fluoxetine. In the present study, the effect of chronic management of the combination of fluoxetine and a 5-HT1A receptor agonist anxiolytic buspirone was examined in order to correct the adverse effects of prenatal stress on pain and affective behavior in the female offspring during the prepubertal period of development. It was found that the immobilization stress of rat dams in the last third of pregnancy (the stress of rat dams during pregnancy is used as a model of human depression) caused in the offspring the increased functional activity of the pain system, an increase in the level of depressive-like behavior. Chronic administration to pregnant dams of fluoxetine, buspirone, or their combination has improved the characteristics under study in the female offspring. The results indicate that the chronic administration of a combination of fluoxetine and buspirone during the gestation of rat dams neutralized the negative effect of prenatal stress in female offspring. More effective action of the combination of the drugs compared with the action of fluoxetine was revealed in the pain sensitivity to thermal stimulus and in the first acute phase of pain behavior in the formalin test. Undesirable deviations in the investigated types of behavior in female rats subjected to pharmacological effects of each of the drugs during the prenatal period were not revealed.

show abstract

“…This can lead to increased side effects but more often to the effectiveness of a drug in a different aspect of the same disease or in more than one disease, expanding its clinical utility [Morphy and Rankovic, 2008;Wong et al, 2010]. Some others drugs were specifically, and not serendipitously, synthesized with the purpose to contemporarily bind different proteins and provide an improvement of the effectiveness (i.e., agomelatine, vilazodone) [Dawson and Watson, 2009;Guardiola-Lemaitre et al, 2014;Wang et al, 2016]. Table 1 shows some examples of drugs with their main and secondary mechanisms of action and some examples of drugs designed to contemporarily bind two different receptors involved in the same disease.…”

Section: Multitarget Drug Approach In Antipsychotic Drug Discoverymentioning

confidence: 99%

Perspectives in Designing Multifunctional Molecules in Antipsychotic Drug Discovery

Milelli

Turrini

Catanzaro

et al. 2016

Drug Development Research

View full text Add to dashboard Cite

Preclinical Research A novel and promising approach to overcome the limits of single-target therapy is represented by the multitarget approach. This strategy aims to simultaneously modulate several targets involved in the pathophysiology of a multifactorial disease, with the potential to enhance therapeutic effectiveness and improve drug safety. Although there has been a marked growth in the design of multitarget drugs (MTDs) in the last years in the context of anti-Alzheimer and anti-cancer drug discovery, a parallel expansion was not observed in antipsychotic drugs, even that for psychiatric disorders there is a cogent medical need for new treatments. The discovery of new MTDs is a challenging task and we will describe the main strategies that have been developed over the years for the design of multifunctional molecules in antipsychotic drug discovery. In particular, we will focus on the few available MTDs based on the design of selective serotonin re-uptake inhibitors, used as antidepressants and in the treatment of schizophrenia. Drug Dev Res 77 : 437-443, 2016. © 2016 Wiley Periodicals, Inc.

show abstract

Vilazodone for the Treatment of Depression: An Update

Cited by 41 publications

References 46 publications

A Review of the Pharmacological and Clinical Profile of Newer Atypical Antipsychotics as Treatments for Bipolar Disorder: Considerations for Use in Older Patients

A Review of the Pharmacological and Clinical Profile of Newer Atypical Antipsychotics as Treatments for Bipolar Disorder: Considerations for Use in Older Patients

Correction of pain-related and affective behavior by combination of fluoxetine and buspirone in prenatally stressed rats

Perspectives in Designing Multifunctional Molecules in Antipsychotic Drug Discovery

Contact Info

Product

Resources

About